AU2014206553B2 - miRNA-124 as a biomarker - Google Patents
miRNA-124 as a biomarker Download PDFInfo
- Publication number
- AU2014206553B2 AU2014206553B2 AU2014206553A AU2014206553A AU2014206553B2 AU 2014206553 B2 AU2014206553 B2 AU 2014206553B2 AU 2014206553 A AU2014206553 A AU 2014206553A AU 2014206553 A AU2014206553 A AU 2014206553A AU 2014206553 B2 AU2014206553 B2 AU 2014206553B2
- Authority
- AU
- Australia
- Prior art keywords
- mirna
- group
- quinoline derivative
- mir
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019283919A AU2019283919A1 (en) | 2013-01-17 | 2019-12-19 | miRNA-124 as a biomarker |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305053.4A EP2757161A1 (en) | 2013-01-17 | 2013-01-17 | miRNA-124 as a biomarker of viral infection |
| EP13305053.4 | 2013-01-17 | ||
| PCT/IB2014/058359 WO2014111892A1 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 AS A BIOMARKER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019283919A Division AU2019283919A1 (en) | 2013-01-17 | 2019-12-19 | miRNA-124 as a biomarker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014206553A1 AU2014206553A1 (en) | 2015-07-23 |
| AU2014206553B2 true AU2014206553B2 (en) | 2020-01-16 |
Family
ID=47628077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014206553A Active AU2014206553B2 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 as a biomarker |
| AU2019283919A Abandoned AU2019283919A1 (en) | 2013-01-17 | 2019-12-19 | miRNA-124 as a biomarker |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019283919A Abandoned AU2019283919A1 (en) | 2013-01-17 | 2019-12-19 | miRNA-124 as a biomarker |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11441181B2 (https=) |
| EP (2) | EP2757161A1 (https=) |
| JP (1) | JP6607568B2 (https=) |
| KR (2) | KR102412581B1 (https=) |
| CN (1) | CN105612261B (https=) |
| AU (2) | AU2014206553B2 (https=) |
| BR (1) | BR112015016977B1 (https=) |
| CA (1) | CA2897563C (https=) |
| DK (1) | DK2946022T3 (https=) |
| ES (1) | ES2716104T3 (https=) |
| HR (1) | HRP20190436T1 (https=) |
| MX (1) | MX363726B (https=) |
| PL (1) | PL2946022T3 (https=) |
| PT (1) | PT2946022T (https=) |
| RU (1) | RU2687366C2 (https=) |
| TR (1) | TR201903401T4 (https=) |
| WO (1) | WO2014111892A1 (https=) |
| ZA (1) | ZA201504984B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN105530938B (zh) * | 2013-07-05 | 2019-10-22 | Abivax公司 | 用于治疗由逆转录病毒引起的疾病的化合物 |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| US20220073988A1 (en) * | 2018-12-07 | 2022-03-10 | Dna Chip Research Inc. | Method for predicting efficacy of rheumatoid arthritis therapeutic agent and biomarker used therein |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| EP3670659A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| WO2020161206A1 (en) * | 2019-02-05 | 2020-08-13 | Universidade De Santiago De Compostela | In vitro method for the diagnosis of viral infections |
| EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| CA3172179A1 (en) | 2020-03-20 | 2021-09-23 | Jamal Tazi | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| CN121532389A (zh) * | 2023-08-30 | 2026-02-13 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
| WO2026020029A1 (en) * | 2024-07-19 | 2026-01-22 | Nextgen Jane, Inc. | Methods for analyzing cervicovaginal samples |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (https=) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| US4738710A (en) | 1979-11-19 | 1988-04-19 | Ici Australia Limited | Herbicidal alkane carboxylic acid derivatives |
| FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| CA2368688C (en) | 1999-04-05 | 2009-08-11 | City Of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| KR100856622B1 (ko) | 2001-01-22 | 2008-09-03 | 메모리 파마슈티칼스 코포레이션 | 포스포디에스테라제 4 억제제 |
| US6498254B1 (en) * | 2001-10-29 | 2002-12-24 | Uniroyal Chemical Company, Inc. | Antiretroviral compounds and compositions |
| MXPA04011472A (es) | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2003256616B2 (en) | 2002-07-19 | 2009-08-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| CA2518398A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| US7691866B2 (en) | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| EP1758581A1 (en) * | 2004-05-21 | 2007-03-07 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
| WO2006051311A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| US20090088513A1 (en) | 2005-06-29 | 2009-04-02 | Adeka Corporation | Resin additive composition and resin composition |
| AU2006300864A1 (en) * | 2005-10-10 | 2007-04-19 | Council Of Scientific And Industrial Research | Human microrna targets in HIV genome and a method of identification thereof |
| RU2350650C2 (ru) * | 2006-04-17 | 2009-03-27 | Общество с ограниченной ответственностью "Биосинтез" (ООО "Биосинтез") | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pVar15-HIV-LTR, НЕСУЩАЯ КЛОНИРОВАННЫЙ ФРАГМЕНТ ГЕНОМА ВИЧ-1 ТИПА ИЗ КОНСЕРВАТИВНОГО УЧАСТКА 5'-LTR ПОСЛЕДОВАТЕЛЬНОСТИ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBluKSM-HIV-LTR mod, НЕСУЩАЯ КЛОНИРОВАННЫЙ МОДИФИЦИРОВАННЫЙ ФРАГМЕНТ ЭТОГО ЖЕ УЧАСТКА ГЕНОМА ВИЧ-1 ТИПА, ТЕСТ-НАБОР ДЛЯ КОЛИЧЕСТВЕННОЙ ЭКСПРЕСС-ИДЕНТИФИКАЦИИ ГЕНОМА ВИЧ-1 ЛЮБОГО ТИПА В ПРОБЕ И СПОСОБ С ЕГО ИСПОЛЬЗОВАНИЕМ |
| US8163760B2 (en) | 2006-06-22 | 2012-04-24 | Prana Biotechnology Limited | Use of pyridopyrimidine compounds in the treatment of gliomas |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| KR20090111847A (ko) | 2007-01-19 | 2009-10-27 | 아디아 바이오사이언스즈 인크. | Ｍｅｋ 억제제 |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| WO2008115870A2 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| CN101679150B (zh) | 2007-05-17 | 2013-05-15 | Lg化学株式会社 | 蒽衍生物和使用该蒽衍生物的有机电子器件 |
| WO2008153692A2 (en) * | 2007-05-22 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | Microrna expression profiling of cerebrospinal fluid |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| CN101801194A (zh) | 2007-08-15 | 2010-08-11 | 记忆医药公司 | 具有5-ht6受体亲和力的3’取代的化合物 |
| WO2009029617A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| KR100974562B1 (ko) | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| JP2009174368A (ja) | 2008-01-23 | 2009-08-06 | Toyota Motor Corp | 内燃機関の排気浄化装置 |
| WO2009132273A2 (en) * | 2008-04-25 | 2009-10-29 | Merck & Co., Inc. | Microrna biomarkers of tissue injury |
| US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
| JP2012520891A (ja) * | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホニルキノリンの製造方法 |
| WO2010129451A1 (en) | 2009-05-05 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| HRP20191460T1 (hr) | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
| US8648017B2 (en) * | 2009-11-04 | 2014-02-11 | Diamir, Llc | Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| WO2012118988A1 (en) * | 2011-03-01 | 2012-09-07 | The Scripps Research Institute | Direct reprogramming of human fibroblasts to functional neurons under defined conditions |
| SI2756099T1 (sl) * | 2011-09-15 | 2017-11-30 | Self-Screen B.V. | Postopek za detekcijo HPV-induciranega raka materničnega vratu |
| WO2014055944A1 (en) | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| PT3429998T (pt) | 2016-03-18 | 2021-11-04 | Prosynergia S A R L | Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais |
-
2013
- 2013-01-17 EP EP13305053.4A patent/EP2757161A1/en not_active Withdrawn
-
2014
- 2014-01-17 EP EP14703438.3A patent/EP2946022B1/en active Active
- 2014-01-17 RU RU2015133373A patent/RU2687366C2/ru active
- 2014-01-17 CA CA2897563A patent/CA2897563C/en active Active
- 2014-01-17 CN CN201480011638.3A patent/CN105612261B/zh active Active
- 2014-01-17 TR TR2019/03401T patent/TR201903401T4/tr unknown
- 2014-01-17 MX MX2015008703A patent/MX363726B/es active IP Right Grant
- 2014-01-17 WO PCT/IB2014/058359 patent/WO2014111892A1/en not_active Ceased
- 2014-01-17 KR KR1020157022175A patent/KR102412581B1/ko active Active
- 2014-01-17 PL PL14703438T patent/PL2946022T3/pl unknown
- 2014-01-17 KR KR1020227009514A patent/KR102575595B1/ko active Active
- 2014-01-17 US US14/761,674 patent/US11441181B2/en active Active
- 2014-01-17 DK DK14703438.3T patent/DK2946022T3/en active
- 2014-01-17 ES ES14703438T patent/ES2716104T3/es active Active
- 2014-01-17 BR BR112015016977-5A patent/BR112015016977B1/pt active IP Right Grant
- 2014-01-17 HR HRP20190436TT patent/HRP20190436T1/hr unknown
- 2014-01-17 PT PT14703438T patent/PT2946022T/pt unknown
- 2014-01-17 JP JP2015553212A patent/JP6607568B2/ja active Active
- 2014-01-17 AU AU2014206553A patent/AU2014206553B2/en active Active
-
2015
- 2015-07-10 ZA ZA2015/04984A patent/ZA201504984B/en unknown
-
2019
- 2019-12-19 AU AU2019283919A patent/AU2019283919A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015133373A (ru) | 2017-02-21 |
| CN105612261A (zh) | 2016-05-25 |
| BR112015016977A2 (https=) | 2017-08-15 |
| BR112015016977B1 (pt) | 2022-11-08 |
| ES2716104T3 (es) | 2019-06-10 |
| US20150361491A1 (en) | 2015-12-17 |
| WO2014111892A1 (en) | 2014-07-24 |
| EP2946022A1 (en) | 2015-11-25 |
| KR20220038551A (ko) | 2022-03-28 |
| JP2016505268A (ja) | 2016-02-25 |
| KR102575595B1 (ko) | 2023-09-06 |
| EP2757161A1 (en) | 2014-07-23 |
| HRP20190436T1 (hr) | 2019-06-14 |
| TR201903401T4 (tr) | 2019-04-22 |
| RU2687366C2 (ru) | 2019-05-13 |
| CA2897563C (en) | 2021-08-31 |
| HK1218766A1 (zh) | 2017-03-10 |
| MX363726B (es) | 2019-04-01 |
| MX2015008703A (es) | 2016-04-15 |
| ZA201504984B (en) | 2016-09-28 |
| PL2946022T3 (pl) | 2019-06-28 |
| CN105612261B (zh) | 2019-06-18 |
| JP6607568B2 (ja) | 2019-11-20 |
| CA2897563A1 (en) | 2014-07-24 |
| KR102412581B1 (ko) | 2022-06-23 |
| KR20150109407A (ko) | 2015-10-01 |
| AU2014206553A1 (en) | 2015-07-23 |
| EP2946022B1 (en) | 2019-01-09 |
| US11441181B2 (en) | 2022-09-13 |
| DK2946022T3 (en) | 2019-04-08 |
| AU2019283919A1 (en) | 2020-01-16 |
| PT2946022T (pt) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014206553B2 (en) | miRNA-124 as a biomarker | |
| JP7550425B2 (ja) | 炎症性疾患の処置のためのキノリン誘導体 | |
| JP5965481B2 (ja) | 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の診断用マイクロｒｎａプロファイリング | |
| JP2022188086A (ja) | 子宮内膜症についてのバイオマーカーとしてのマイクロｒｎａ | |
| BR112013033488B1 (pt) | Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit | |
| CN109837340B (zh) | 用于肺癌无创诊断的外周血基因标记物 | |
| EP3143162A1 (en) | Mirna expression signature in the classification of thyroid tumors | |
| JP7235508B2 (ja) | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 | |
| CN104066842A (zh) | Hiv检测用寡核苷酸、hiv检测试剂盒及hiv检测方法 | |
| TWI698640B (zh) | 用於檢測狼瘡性腎炎或評估狼瘡性腎炎風險的方法及其應用 | |
| US20150119447A1 (en) | Clustered single nucleotide polymorphisms in the human acetylcholinesterase gene and uses thereof in diagnosis and therapy | |
| JP2017143810A (ja) | 抗酸菌症又は抗酸菌感染のバイオマーカー | |
| HK1218766B (zh) | 作为生物标记物的mirna-124 | |
| US20100015620A1 (en) | Cancer-linked genes as biomarkers to monitor response to impdh inhibitors | |
| KR20120001917A (ko) | 아스피린 과민성 두드러기의 진단용 ｓｎｐ 유전자 세트 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |